跳至主要内容
临床试验/IRCT20210513051280N2
IRCT20210513051280N2尚未招募1 期

Assessment of safety and effectiveness of intrauterine infusion of allogeneic menstrual blood stem cells in women with unexplained recurrent pregnancy loss: A double-blind phase 1 and 2 clinical trial

Iranian academic center for education culture and research0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 37 years(—)
性别
Female

入选标准

  • Women with primary recurrent pregnancy losses (at least two successive pregnancy losses excluding blighted ovum confirmed by sonography or pathology till 10th week of gestation
  • Maximum patient age: 37 years, no history of previous live birth
  • FSH level of less than 10 mIU/mL
  • Negative test results for HIV, HBS Ag, HCV and VDR

排除标准

  • Having previous history of successful pregnancy
  • Chromosomal abnormalities in parents
  • Uterine anatomic abnormalities
  • Hormonal abnormalities
  • PCO with metabolic syndrome
  • Uncontrolled diabetes
  • Stage 3 or 4 endometriosis
  • Autoimmune diseases including rheumatoid arthritis, thyroid autoimmunity, lupus and anti-phospholipid antibodies
  • History of cancer, chemotherapy and radiotherapy
  • Spermogram abnormalities (DFI more than 30 and normal sperm morphology less than 2%
  • History of immunosuppressive drugs intake including corticosteroids during the past three months

研究者

发起方
Iranian academic center for education culture and research

相似试验